Experimental Pain Perception Clinical Trial
| Verified date | October 2017 |
| Source | Rambam Health Care Campus |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The role of alpha2 receptor agonist on pain perception and modulation will be examined. In addition whether this is mediated through the opioid system will be examined. Pain perception and modulation will be examined before and after administration of Clonidine or placebo together with Naloxone or saline.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | September 2016 |
| Est. primary completion date | September 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 40 Years |
| Eligibility |
Inclusion Criteria: - Healthy volunteers - Age 18-40 - No chronic disease Exclusion Criteria: - Subjects who suffer from chronic pain / pain syndrome - use of anti-depressant or anti-psychotic drugs - suffering from cardiovascular disease - breast feeding |
| Country | Name | City | State |
|---|---|---|---|
| Israel | Rambam Health Care Campus | Haifa |
| Lead Sponsor | Collaborator |
|---|---|
| Rambam Health Care Campus |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist | The change in pain perception (pain thresholds and pain ratings of suprathresholds stimuli) and in the excitatory and inhibitory pain modulation responses (assessed by the temporal summation and conditioned pain modulation paradigms) will be examined before and after administration of alpha 2 agonist with and without mu receptor antagonist | 2 years |